AF solution
Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
Summary: Test, Setting A New Benchmark in Non-Invasive Colorectal Cancer Screening Exact Sciences announces that the FDA has approved their Cologuard Plus Test, an advanced screening test for colorectal cancer. Cologuard Plus is an enhanced version of the company’s previous Cologuard test and now includes additional biomarkers that help improve the detection of colorectal cancer and precancerous lesions. This approval marks a significant step in the early detection of colon cancer, allowing for more accurate screening, potentially leading to better outcomes for patients.
Summary: Sammy Basso, who was the longest living survivor of the rare genetic disease progeria, has died at the age of 28, the Italian Progeria Association said on Sunday.
Progeria, also known as Hutchinson–Gilford syndrome (HGPS), causes people to age rapidly, leading them to appear older than they are, with a reduced quality of life and a life expectancy of only 13.5 years without treatment, the association’s website said.
Summary: From antibody-drug conjugates to immuno-oncology checkpoint inhibitors, China is the world’s most closely watched rising biotechnology power.
The growth of China’s industry can be attributed to a number of factors, including beneficial state policies and fresh injections of funding. There has also been bold regulatory reform.
Summary: Kurma Partners announced a first closing of its new Biofund IV at €140m targeted to raise €250m to finance 16-20 life science companies
Paris-based asset management firm Kurma Partners has completed the first closing of Biofund IV, raising €140 million. Kurma aims to raise a total of €250 million by the final closing in 2025, making it their largest venture capital investment fund to date.
Biofund IV targets 16 to 20 new investments, of which the first three have already been made. Like its predecessors, Biofund IV will be dedicated to companies developing innovative therapeutics, aiming for a balanced risk management strategy with investments in both company creation and existing venture-stage companies. Kurma remains thematically agnostic and will continue to opportunistically pursue the forefront of innovation to identify and create future industry trends.
Summary: Orthocell has achieved its second consecutive quarter of record revenue, reporting $2.03 million for Q1 FY25, up 7.82% from the previous quarter. The growth is driven by increased sales of their products Striate+ and Remplir, which are used in dental and nerve repair procedures. The company is expanding its market presence in key regions, including the U.S., Europe, and Australia. With strong financial backing and regulatory approvals in progress, Orthocell is positioned for continued growth in the global regenerative medicine market.
@ 2024 . All rights reserved
@ 2024 . All rights reserved
